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Development and evaluation of a molecular assay for detection
of nontuberculous mycobacteria on the basis of the COBAS
Amplicor platform
Abstract
We have developed and evaluated a semiautomated assay for detection of nontuberculous mycobacteria
(NTM) from clinical samples based on the COBAS Amplicor M. tuberculosis test (Roche Diagnostics,
Switzerland). A capture probe, specific for mycobacteria at the genus level, was linked to magnetic
beads and used for the detection of amplification products obtained by the COBAS Amplicor M.
tuberculosis assay. We demonstrate that the analytical sensitivity of the genus assay is similar to that of
COBAS Amplicor M. tuberculosis detection. 416 clinical specimens were evaluated for the presence of
NTM DNA. Sensitivity for smear positive and smear negative specimens was found to be 100 % and
47.9 %, respectively. Specificity was 97.7 %, the positive predictive value (PPV) 84.6 % and the
negative predictive value (NPV) 93.1 %. The genus assay is easy to perform, produces reliable results
and was found to be a valuable diagnostic tool for rapid diagnosis of infections with NTM. The genus
assay has the potential to detect NTMs not routinely recovered by culture and to discover new
mycobacterial species.
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We have developed and evaluated a semiautomated assay for detection of nontuberculous mycobacteria
(NTM) from clinical samples based on the Cobas AmplicorMycobacterium tuberculosis test (Roche Diagnostics,
Switzerland). A capture probe, specific for mycobacteria at the genus level, was linked to magnetic beads and
used for the detection of amplification products obtained by the Cobas Amplicor M. tuberculosis assay. We
demonstrate that the analytical sensitivity of the genus assay is similar to that of Cobas Amplicor M.
tuberculosis detection. Four hundred sixteen clinical specimens were evaluated for the presence of NTM DNA.
Sensitivities for smear-positive and smear-negative specimens were found to be 100% and 47.9%, respectively.
Specificity was 97.7%, the positive predictive value 84.6%, and the negative predictive value 93.1%. The genus
assay is easy to perform, produces reliable results, and was found to be a valuable diagnostic tool for rapid
diagnosis of infections with NTM. The genus assay has the potential to detect NTM not routinely recovered by
culture and to discover new mycobacterial species.
Nontuberculous mycobacteria (NTM) are frequently iso-
lated from environmental sources, and about one-third of the
species described have been associated with human disease
(11, 16). Their pathogenic potential is variable, and infections
preferentially occur in patients with underlying immunocom-
promising conditions, although immunocompetent individuals
can also be affected. Clinical conditions caused by NTM in-
clude cutaneous ulcers, soft-tissue infections, lymphadenitis,
joint infections, lung disease, and disseminated infections (11).
Rapid laboratory diagnosis and differentiation from Mycobac-
terium tuberculosis are crucial, since treatment of NTM differs
significantly from that of M. tuberculosis infections. Given the
slow growth of most mycobacteria, fast and accurate molecular
techniques are important for the diagnosis of suspected myco-
bacterial infections.
A variety of PCR-based test systems for direct detection of
M. tuberculosis complex DNA from clinical specimens are com-
mercially available and widely used, e.g., Cobas Amplicor M.
tuberculosis (Roche Diagnostics, Switzerland) and AMTD2
(Gen-Probe) (15). In contrast, molecular genetic assays for
direct detection of NTM are only infrequently implemented in
routine diagnostics, although various in-house assays have
been described (2, 4, 5, 8, 12, 21, 22). This is mainly due to the
fact that existing assays are time-consuming and evaluation
data are limited. Recently a commercial assay based on a
manual line blot format was released for the direct detection of
M. tuberculosis, M. avium, M. intracellulare, M. kansasii and M.
malmoense from clinical samples (Hain Lifescience, Nehren,
Germany) (7). However, numerous NTM well known to cause
disease in humans are not included in this assay (e.g., M.
marinum, M. abscessus, M. chelonae, M. xenopi, and M. ulcer-
ans) (1, 6, 11, 14).
Here we present the development of an assay capable of
detecting a large number of nontuberculous mycobacteria
from clinical specimens using a semiautomated system well
established for the detection of M. tuberculosis complex DNA.
MATERIALS AND METHODS
Decontamination of specimens, microscopy, and culture. Specimens were
decontaminated using the N-acetyl-L-cysteine-sodium hydroxide method for
respiratory samples or the sodium hydroxide method for samples from sterile
sites, following standard protocols (10). Microscopy was performed using aura-
mine-rhodamine fluorochrome staining; positive microscopy results were con-
firmed using Ziehl-Neelsen staining (10). Standard media (Lo¨wenstein-Jensen,
7H11 plates, and BBL MGIT [Becton, Dickinson and Company]) were used for
cultural recovery, and cultures were incubated for 8 weeks at 37°C. For speci-
mens from sterile sites, microscopy and inoculation of culture media were per-
formed prior to decontamination. Mycobacteria grown in culture were identified
by sequence analysis of the 16S rRNA gene as described previously (3, 12).
Clinical specimens. Over a period of 3 months, the genus assay was performed
with all samples for which molecular detection of M. tuberculosis was requested.
In addition, we retrospectively included patient samples in the study which were
positive for NTM by culture to allow calculation of sensitivity. Retrospectively
analyzed samples were decontaminated and stored at 4°C prior to DNA extrac-
tion.
Although the Cobas Amplicor M. tuberculosis test is approved only for respi-
ratory specimens, it is also widely used for nonrespiratory specimens (13, 17, 20,
24). Consequently, we included respiratory as well as nonrespiratory specimens
in our study.
DNA extraction. DNA was extracted from 0.5 ml of decontaminated specimen
using the respiratory specimen preparation kit (Roche Diagnostics, Switzerland),
following instructions for the Cobas Amplicor M. tuberculosis test (18).
Detection ofM. tuberculosis complex DNA. The Cobas Amplicor M. tuberculosis
test was performed according to the manufacturer’s instructions (Roche Diag-
nostics, Switzerland). Briefly, 50 l master mix containing AmpliTaq DNA poly-
merase, biotinylated primers KY18 and K75, and an internal control plasmid
were transferred into the detection ring, and 50 l of DNA extract was added.
The denaturation reagent, conjugate reagent, substrate, internal control detec-
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tion reagent, and M. tuberculosis detection reagent were applied to the Cobas
Amplicor analyzer as described in the operator’s manual (18). Results were
interpreted according to the manufacturer’s instructions. A run was considered
valid if the optical density at 660 nm (OD660) of the positive control was2.0 and
the OD660 of the negative control was 0.25. A sample was interpreted as
positive if the OD660 was 0.35. A sample was interpreted as negative if the
OD660 was 0.35 and the OD660 of the internal inhibition control was 0.35.
Labeling of magnetic beads with Mycobacterium genus-specific capture probe.
To adapt the Cobas Amplicor M. tuberculosis platform for the detection of
nontuberculous mycobacteria, we constructed a Mycobacterium genus-specific
capture probe. Magnetic beads harboring carboxylic acid groups on their sur-
faces were coupled to a Mycobacterium genus-specific oligonucleotide probe with
an amino modification. Magnetic beads (Dynabeads M-270 carboxylic acid; In-
vitrogen, Germany) were washed four times with 25 mM 2-(N-morpholino)eth-
anesulfonic acid (MES) (Sigma-Aldrich Chemie GmbH, Germany) (pH 5) and
incubated with oligonucleotide 259 (12) carrying an amino modification at the
5end (5 NH2-TTT CAC GAA CAA CGC GAC AA; tib molbiol, Germany) at
a concentration of 2.1 nmol oligonucleotide per mg beads for at least 30 min at
room temperature. Subsequently, N-(3-dimethylaminopropyl)-N-ethylcarbodi-
imide HCl (EDC) (Sigma-Aldrich Chemie GmbH, Germany), resolved in cold
100 mM MES (pH 5), was added to the beads at a concentration of 10 mg per
mg beads and incubated overnight at 4°C with shaking at 900 rpm. Labeled beads
were washed four times using 50 mM Tris-HCl (pH 7.4) and stored in 50 mM
Tris-HCl–0.1% Tween 20–0.02% sodium azide (pH 7.4) at 4°C until usage. All
buffers were subjected to sterile filtration using a vacuum filtration system
equipped with 0.22-m membrane filters (Techno Plastic Product, Switzerland).
Detection of Mycobacterium genus DNA using Cobas Amplicor platform. For
detection of Mycobacterium genus DNA, we prepared a Mycobacterium genus-
specific detection reagent. Beads labeled with the genus-specific probe (4.5 mg)
were washed four times with 50 mM Tris (pH 7.4), resuspended in 1.3 ml of 25
mM MES–sodium azide (0.09%) (pH 9.18), and added to 6 ml of internal control
buffer (Roche Diagnostics, Switzerland) in the original vial of the internal control
buffer. The amount of beads used was adjusted by photometric measurement to
an OD600 of 0.9 to 1.2.
The genus assay was performed on the Cobas Amplicor analyzer. For the
detection of Mycobacterium genus DNA, the Mycobacterium genus detection
reagent was applied to the analyzer instead of a detection reagent for M. tuber-
culosis DNA. A random barcode for an MTB detection vial was chosen in the
Cobas analyzer software system, containing a “2” at the third position (MT2. . .),
which indicated that the detection reagent was sufficient for 50 tests. This ran-
dom barcode was then assigned to the Mycobacterium genus detection reagent.
The rest of the procedure was identical to that of the Cobas Amplicor M.
tuberculosis assay (18). To test a sample for the presence of both M. tuberculosis
and Mycobacterium genus DNA, the Cobas Amplicor M. tuberculosis test was
performed first. Subsequently, the ring containing the amplification products was
transferred to the inner detection position and the same amplification products
were detected again using the Mycobacterium genus detection reagent. The
following algorithm was used for the interpretation of the genus assay. A run was
considered valid if the OD660 of the positive control was 2.0 and the OD660 of
the negative control was 0.5. A sample was considered positive if the OD660
was 0.5 and at least twofold higher than the background (negative control). A
sample was considered negative if the OD660 was 0.5 and the OD660 of the
internal control was 0.35. Samples with inhibition of amplification were ex-
cluded from the analysis.
Amplification, DNA purification, and sequencing of genus assay-positive sam-
ples. Samples positive in the genus assay were amplified in a separate PCR to
allow for sequence analysis without interference by the internal control plasmid.
For additional PCRs, the same DNA extract was used. PCR amplification (95°C
for 12 min and 40 cycles of 95°C for 1 min, 64°C for 1 min, 72°C for 2 min, and
72°C for 12 min) was performed in a total volume of 100 l containing 5 U
FastStart DNA polymerase, 1 PCR buffer with MgCl2 (Roche Diagnostics,
Switzerland), 0.4 M primer KY18 (5-CAC ATG CAA GTC GAA CGG AAA
GG; tib molbiol, Germany) (23), 0.4 M primer KY75 (5-GCC CGT ATC GCC
CGC ACG CTC ACA) (23), 0.2 mM deoxynucleoside triphosphates (PCR
nucleotide mix; Roche Diagnostics, Switzerland), and 20 l of specimen DNA
extract. Following purification of the PCR product (PCR purification kit, Qia-
gen, Germany) and cycle sequencing with primer Mbakt-14 (5-GRG RTA CTC
GAG TGG CGA AC [tib molbiol, Germany] and Avant 3100 [Applied Biosys-
tems, Switzerland]), sequence analysis for species identification was performed
as described previously (3). In the case of unsatisfactory sequence quality, the
PCR product was reamplified (95°C for 12 min and 40 cycles of 95°C for 1 min,
58°C for 1 min, 72°C for 2 min, and 72°C for 12 min) using a seminested PCR
approach with 2.5 U FastStart DNA polymerase including PCR buffer with
MgCl2 (Roche Diagnostics, Switzerland), 0.4 M primer KY18, 0.4 M primer
259 (5 TTT CAC GAA CAA CGC GAC AA; Tib Molbiol, Germany), 0.2 mM
deoxynucleoside triphosphates (PCR nucleotide mix; Roche Diagnostics, Swit-
zerland), and 2.5 l PCR product in a total volume of 50 l. If no PCR product
could be obtained, amplification and reamplification were repeated as described
above using alternative primer pairs 283 (5-GAG TTT GAT CCT GGC TCA
GGA, tib molbiol, Germany)/264 (5-TGC ACA CAG GCC ACA AGG GA; tib
molbiol, Germany) for amplification and primers 283/259 for reamplification.
The resulting PCR product was subjected to purification, cycle sequencing, and
sequence analysis as described above.
RESULTS
Establishment of direct detection assay for Mycobacterium
genus DNA from clinical specimens. We developed and vali-
dated an assay for direct detection of nontuberculous myco-
bacteria from clinical specimens using the Cobas Amplicor
platform. Briefly, the Cobas Amplicor M. tuberculosis assay
includes the following steps: (i) isolation of DNA from clinical
samples, (ii) amplification of a 584-bp fragment of the 16S
rRNA gene with biotinylated panmycobacterial primers (2,
23), (iii) capture of the PCR product with an M. tuberculosis-
specific probe linked to magnetic beads, and (iv) photometric
detection of the captured PCR product. The reaction mix
contains an internal control plasmid to control for inhibition of
the PCR. In order to use the Cobas Amplicor platform for the
detection of nontuberculous mycobacteria, we generated a My-
cobacterium genus-specific capture probe to be used as the
specific detection reagent. Samples positive in the genus assay
were amplified with panmycobacterial primers, and resulting
amplification products were subjected to nucleic acid sequence
determination to identify the Mycobacterium species.
Sensitivity of the genus assay compared to the Cobas Am-
plicor M. tuberculosis test. The analytical sensitivity of the ge-
nus assay was determined using a dilution series of M. tuber-
culosis DNA (H37RV) and compared to that of the Cobas
Amplicor M. tuberculosis assay. The detection limit of both
assays was 8 to 80 fg DNA per PCR, which is equivalent to
approximately 2 to 20 genome copies (molecular weight of the
M. tuberculosis genome, 4 fg) (9) (Fig. 1). Clinical evaluation
showed that 15 of 431 specimens tested positive for the pres-
ence of M. tuberculosis DNA using the Cobas Amplicor M.
tuberculosis assay. All 15 samples also gave a positive result
using the genus assay (data not shown), further indicating that
the genus assay is as sensitive as the commercial Cobas Am-
plicor M. tuberculosis assay.
Evaluation of the genus assay with clinical specimens. To
evaluate the performance of the genus assay on clinical sam-
ples, the assay was incorporated into the routine diagnostic
workflow. Samples screened for the presence of M. tuberculosis
DNA were subsequently tested for the presence of NTM DNA
using the genus assay. This strategy enabled us to screen a large
number of clinical samples for the presence of NTM DNA
using a semiautomated platform.
In total, 467 specimens were tested for the presence of M.
tuberculosis and Mycobacterium genus DNA. This included 342
respiratory and 125 nonrespiratory specimens (46 puncture
specimens, including aspirates from the pleural and abdominal
cavities, 42 biopsies, 13 CSFs, 15 urines, 4 gastric aspirates, 3
stool samples, and 2 bone marrow specimens).
Inhibition of amplification as determined by negative inter-
nal control signals was detected in 36 of 467 (7.8%) specimens.
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In 15 (3.5%) of the remaining 431 samples, M. tuberculosis
DNA was detected by both the genus assay and the Cobas
Amplicor M. tuberculosis test (see above). These samples
were excluded from the evaluation of the genus assay; thus,
a total of 416 specimens were evaluated for the presence of
NTM DNA.
In the genus assay, 52 of the 416 (12.5%) specimens tested
positive, and the Mycobacterium species was further deter-
mined by sequence analysis. Samples were considered to be
true positive in the genus assay if (i) the corresponding NTM
was grown in culture, (ii) the corresponding NTM could be
cultivated from other samples of the same patient, or (iii) the
assay identified a noncultivable Mycobacterium species associ-
ated with a typical disease (e.g., M. leprae).
For 39 of 52 (75.0%) of the genus assay-positive samples
species, identity was confirmed by culture (Table 1). Mycobac-
terial culture was negative for 13 samples positive in the genus
assay. These discrepant samples were further analyzed to de-
termine if NTM infection was present in the corresponding
patients (Table 2). Three of the thirteen samples originated
from patients with confirmed M. kansasii infections and were
thus considered true positives. Two of the thirteen samples
revealed the presence of M. leprae DNA; these samples were
likewise considered true positives. For analysis of the remain-
ing eight samples positive in the genus assay, see below.
For 64 specimens, culture revealed growth of nontubercu-
lous mycobacteria (39 genus assay-positive samples and 25
genus assay-negative samples) (Table 1), resulting in a total
number of 69 NTM-positive samples (Table 3). For smear-
positive samples, the genus assay showed a sensitivity of 100%
(21/21). For smear-negative samples, where the number of
acid-fast bacilli can be as low as a single bacterium, the sensi-
tivity was found to be 47.9% (23/48). Taking together smear-
positive and -negative samples, the genus assay was able to
detect 44/69 NTM-positive samples, resulting in an overall
sensitivity of 63.8%. Species detected by the genus assay in-
cluded M. kansasii, M. abscessus, M. chelonae, M. avium, M.
intracellulare, M. xenopi, and M. leprae.
By culture, 347 samples were considered to be negative for
FIG. 1. Determination of analytical sensitivity of the genus assay in comparison to the Cobas Amplicor M. tuberculosis test using a dilution
series of M. tuberculosis DNA. The detection limit of the genus assay (solid black) was similar to the detection limit of the Cobas Amplicor M.
tuberculosis test (gray bars). The positive control and the negative control of the Cobas Amplicor M. tuberculosis test were included.




No. of samples with result









Positive 17 4 0 0
Negative 22 9 25 339
Total 39 13 25 339
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NTM, including 8 genus assay-positive samples (Table 3). All
of the eight genus assay-positive, culture-negative samples
were smear negative. In one sample, sequence analysis re-
vealed Corynebacterium sp., and in another three samples, fast-
growing mycobacteria of uncertain clinical significance were
identified. For the remaining four samples, sequence determi-
nation of the amplification product did not result in a clear
sequence (Table 2).
Taken together, the specificity of the genus assay was 97.7%,
the positive predictive value (PPV) 84.6%, and the negative
predictive value (NPV) 93.1%. Sensitivity, specificity, PPV,
and NPV determined for the Mycobacterium genus assay com-
pare well with those published for the Cobas Amplicor M.
tuberculosis test (15).
DISCUSSION
The possibility of genus-specific molecular assays in detec-
tion of mycobacterial infections has been recognized since the
early 1990s (2). However, it has proven difficult, if not impos-
sible, for routine clinical microbiological laboratories with little
expertise in molecular diagnostics to implement homemade
assays in their diagnostic workflow. To address this issue, we
wished to develop a genus-specific molecular detection assay
for mycobacteria on the basis of a widely available commercial
instrumentation platform. Here we present the development
and evaluation of a semiautomated assay for direct detection
of nontuberculous mycobacteria from clinical samples. The
Cobas Amplicor M. tuberculosis assay is well established in
diagnostic laboratories. An assay based on this system has
several advantages: (i) the basic test and platform are commer-
cially available; (ii) a semiautomated detection system with
little hands-on time allows high throughput, which is especially
important in populations with a high proportion of negative
samples; (iii) the PCR product obtained from the Cobas Am-
plicor M. tuberculosis test allows screening for both M. tuber-
culosis DNA and mycobacterial genus DNA; (iv) the positive
control included in the Cobas Amplicor M. tuberculosis test can
be used as a positive control for the genus assay (by using the
same positive control, the performance of the genus assay can
be directly compared to the Cobas Amplicor M. tuberculosis
test for quality assurance); and (v) an internal control plasmid
is included in the Cobas Amplicor M. tuberculosis test, which
controls for inhibition of amplification.
To determine the analytical sensitivity of the genus assay, we
tested a dilution series of M. tuberculosis DNA and demon-
strated that there is no difference between the detection limit
of the genus assay and that of the Cobas Amplicor M. tuber-
culosis assay (Fig. 1). The detection limit is in accordance with
the published analytical sensitivity for purified DNA of five
genome copies per PCR in 100% of the PCRs (18).
For evaluation of the genus assay in a routine diagnostic
setting, 467 clinical samples were tested for the presence of
mycobacterial DNA. These included 342 respiratory and 125
nonrespiratory specimens. The sensitivities of the genus assay
were found to be 100%, 47.9%, and 63.8% for smear-positive
samples, smear-negative samples, and overall sensitivity,
respectively. These numbers are similar to the sensitivities pub-
lished for the Cobas Amplicor M. tuberculosis test for extrapul-
monary and respiratory specimens, ranging from 87.5 to 100%
for smear-positive samples, from 17.2 to 70.8% for smear-
negative samples, and from 27.3 to 85% for overall sensitivity,
as reviewed by Piersimoni et al. (15). For respiratory speci-










Positive (2.344) M. kansasii/gastri Positive No growth Sputum M. kansasii infectionb
Positive (1.177) M. leprae Positive No growth Biopsy M. leprae infection
Positive (1.173) M. leprae Positive No growth Biopsy M. leprae infection
Positive (3.935) M. kansasii/gastri Positive No growth Sputum M. kansasii infectionb
Positive (1.335) M. kansasii/gastri Negative No growth Sputum M. kansasii infectionb
Positive (0.604) M. frederiksbergense Negative No growth CSFd Unknown significance
Positive (1.359) M. smegmatis Negative No growth Puncture fluid Unknown significance
Positive (1.149) M. fortuitum-complex Negative No growth CSF Unknown significance
Positive (1.059) Corynebacterium sp. Not done No growth Urine False positive
Positive (0.928) No sequencec Negative No growth BALe False positive
Positive (3.772) No sequencec Negative No growth BAL False positive
Positive (4.00) No sequencec Negative No growth Sputum False positive
Positive (4.00) No sequencec Negative No growth CSF False positive
a OD660 of sample in genus assay.
b Positive culture results for other specimens of patient.
c No sequence could be obtained from the amplification product.
d Cerebrospinal fluid.
e Bronchoalveolar lavage.




No. of samples with resulta









Positive 21 0 0 0
Negative 23 25 8 339
Total 44 25 8 339
a A total of 69 samples were positive and 347 negative for NTM.
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mens, the sensitivity for smear-positive and smear-negative
samples and the overall sensitivity, as described in the manual
of the manufacturer, are 96.4%, 72.8% and 86.6%, respectively
(18). We conclude that the sensitivity of the genus assay is
similar to that of the Cobas Amplicor M. tuberculosis test. The
calculated overall sensitivity of the genus assay is relatively low
in our study, since the number of smear-negative samples in-
cluded in the study was more than twofold higher than that of
smear-positive specimens tested.
A total of 52 samples were positive using the genus assay.
Positive PCRs were confirmed by culture for 39 of the 52
samples. The remaining 13 samples were further analyzed to
resolve the discrepancy (Table 2). For three (5.8%) genus
assay-positive, culture-negative samples, sequence analysis of
the PCR product revealed fast-growing mycobacteria of doubt-
ful clinical significance. Given that fast-growing mycobacteria
are found in various environmental sources, these results were
considered most likely to represent contaminants. Since non-
tuberculous mycobacteria are frequently encountered in the
environment, minimizing the risk of specimen contamination
remains challenging. This not only involves assay setup but also
includes all preanalytical steps (sample collection, transport,
processing, decontamination, and DNA extraction). In one
sample, Corynebacterium sp. was detected by nucleic acid anal-
ysis of the PCR product. The 16S rRNA sequences used as
primer target sites in the Cobas Amplicor M. tuberculosis test
are highly conserved within the genus Mycobacterium, includ-
ing the majority of clinically relevant mycobacteria, with the
exception of mycobacteria of the M. simiae group (19, 23).
However, these 16S rRNA sequences are not exclusively spe-
cific for mycobacteria. Cross-reactivity with closely related bac-
teria, such as Corynebacterium species, Norcardia species, and
Rhodococcus species, has been described (23). Cross-reactivity
with these bacteria had only a minor impact on the perfor-
mance of the genus assay, since all positive results were sub-
jected to sequencing. Corynebacterium sp. was identified in 1/52
(1.9%) of genus assay-positive samples, indicating that cross-
reactivity with these genera was a rather rare event in our
evaluation. For four (7.7%) genus assay-positive specimens,
sequence determination of the PCR product did not result in
a defined sequence. Most likely this is a result of unspecific
amplification in the genus assay.
In five (9.6%) genus assay-positive, culture-negative sam-
ples, we identified mycobacteria well established to cause dis-
ease in humans. Three samples revealed M. kansasii. All three
samples were from patients with confirmed M. kansasii infec-
tions. Negative cultures are most likely due to intrasample
variation and impaired viability of the organisms under antibi-
otic therapy. Two samples revealed the presence of M. leprae
DNA; we consider these five samples to be correct positives in
the genus assay.
Our results do point to the potential of the genus assay to
detect mycobacteria which cannot be recovered by culture un-
der normal laboratory conditions. This includes noncultivable
mycobacteria (e.g., M. leprae), mycobacteria with special
growth requirements (e.g., M. ulcerans), very slow-growing my-
cobacteria that exceed routine standard incubation times, and
mycobacteria that fail to be cultivated, e.g., due to antibiotic
therapy or harsh sample decontamination.
The specificity of the genus assay was 97.7%, the PPV
84.6%, and the NPV 93.1%. Again, these values are compara-
ble to the described data for the Cobas Amplicor M. tubercu-
losis test, ranging from 91.3 to 100%, 73.3 to 100%, and 80.8 to
99.2%, respectively (15). The overall specificity, PPV, and
NPV for respiratory specimens published in the manufactur-
er’s manual are 99.7%, 96.3%, and 98.9%, respectively (18).
The eight false-positive samples in the genus assay were
all smear negative and culture negative, and nucleic acid
sequencing of the PCR product revealed sequences of fast-
growing mycobacteria (n  3) or Corynebacterium sp. (n 
1) or did not result in a defined sequence (n  4) (Table 2).
As a result of our evaluation, we report a positive genus
assay result only if one of the following conditions is met: (i)
the identified Mycobacterium species is clearly associated
with disease; (ii) the sample is smear positive; or (iii) the
same sequence has been obtained from other samples of the
patient, which may include the laboratory request for addi-
tional analysis of samples in case only a single sample from
a patient has been submitted to the laboratory. This strategy
can increase the specificity and PPV to close to 100%, al-
though it is difficult to determine true -positive and true-
negative results when cultures remains negative and no
additional reference method is available.
In conclusion, we have successfully developed a direct de-
tection assay for NTM from clinical specimens based on the
Cobas Amplicor M. tuberculosis platform. The genus assay and
subsequent sequence analysis were able to identify the vast
majority, 44/52 (84.6%), of NTM-positive samples correctly.
The Mycobacterium species detected included M. kansasii, M.
abscessus, M. chelonae, M. avium, M. intracellulare, M. xenopi,
and M. leprae, which are all associated with human disease.
The developed assay enables rapid and accurate diagnosis of
infections with NTM, as well as recognition of unknown and
noncultivable mycobacterial species.
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